SeaStar Medical to Report Third Quarter Financial Results on November 13, 2025
SeaStar Medical (Nasdaq: ICU) will report Q3 2025 financial results after market close on Thursday, November 13, 2025, and will host a webcast and conference call at 4:30 p.m. ET / 2:30 p.m. MT with a replay available after 7:30 p.m. ET.
SeaStar is a commercial-stage healthcare company whose first commercial product, QUELIMMUNE (SCD-PED), received FDA approval in 2024 for life-threatening pediatric AKI due to sepsis. The company’s Selective Cytopheretic Device (SCD) has earned Breakthrough Device Designation for six indications and SeaStar is conducting a pivotal adult AKI trial for patients requiring CRRT, a condition the release estimates affects over 200,000 adults annually in the U.S.
SeaStar Medical (Nasdaq: ICU) riferirà i risultati finanziari del III trimestre 2025 dopo la chiusura del mercato di giovedì 13 novembre 2025, e terrà un webcast e una conference call alle 16:30 ET / 14:30 MT con una replica disponibile dopo le 19:30 ET.
SeaStar è una società sanitaria su strada commerciale la cui prima linea di prodotto commerciale, QUELIMMUNE (SCD-PED), ha ricevuto l'approvazione FDA nel 2024 per l'insufficienza renale acuta pediatrica potenzialmente letale dovuta a sepsi. Il dispositivo selettivo citoferetico (SCD) dell'azienda ha ottenuto la Designazione di Dispositivo Innovativo (Breakthrough Device Designation) per sei indicazioni e SeaStar sta conducendo uno studio principale sull'AKI negli adulti per pazienti che necessitano di CRRT, una condizione che, secondo il comunicato, colpisce oltre 200.000 adulti all'anno negli Stati Uniti.
SeaStar Medical (Nasdaq: ICU) informará los resultados financieros del 3er trimestre de 2025 después del cierre del mercado el jueves 13 de noviembre de 2025, y organizará un webcast y una conferencia telefónica a las 16:30 h ET / 14:30 h MT, con una repetición disponible después de las 19:30 h ET.
SeaStar es una empresa de atención médica en etapa comercial cuyo primer producto comercial, QUELIMMUNE (SCD-PED), recibió la Aprobación de la FDA en 2024 para la FAG (insuficiencia renal aguda pediátrica) potencialmente letal causada por sepsis. El dispositivo selectivo citoferetico (SCD) de la empresa ha obtenido la Designación de Dispositivo Innovador (Breakthrough Device Designation) para seis indicaciones y SeaStar está llevando a cabo un ensayo pivotal de AKI en adultos para pacientes que requieren CRRT, una condición que el comunicado estima que afecta a más de 200,000 adultos anualmente en EE. UU..
SeaStar Medical (나스닥: ICU)은 2025년 3분기 재무 실적을 2025년 11월 13일 목요일 장 마감 후 발표하고, 동부 표준시 16:30 / 산악 표준시 14:30에 웨스트캐스트(webcast)와 컨퍼런스 콜을 진행하며, 19:30 ET 이후에 재방송이 제공됩니다.
SeaStar는 상용화 단계의 의료기업으로, 첫 상용 제품인 QUELIMMUNE (SCD-PED)가 2024년 FDA 승인을 받음으로패혈증으로 인한 생명을 위협하는 소아 AKI에 사용됩니다. 회사의 선택적 사이토페테릭 디바이스(SCD)는 여섯 가지 적응증에 대한 혁신적 기기 지정(Breakthrough Device Designation)을 받았으며, SeaStar는 CRRT가 필요한 성인 AKI 환자용 결정적(중요한) 시험을 진행 중이며 이 조건은 발표에 따르면 미국에서 매년 200,000명 이상의 성인에게 영향을 주는 것으로 추정됩니다.
SeaStar Medical (Nasdaq : ICU) publiera les résultats financiers du T3 2025 après la clôture du marché le jeudi 13 novembre 2025, et organisera une webdiffusion et une conférence téléphonique à 16h30 HE / 14h30 MT, avec une reprise disponible après 19h30 HE.
SeaStar est une entreprise de soins de santé en phase commerciale dont le premier produit commercial, QUELIMMUNE (SCD-PED), a reçu l'approbation FDA en 2024 pour l’AKI pédiatrique potentiellement mortelle liée à la septicémie. Le dispositif sélectif citoferétique (SCD) de la société a obtenu la Designation de Dispositif Révolutionnaire pour six indications et SeaStar mènera un essai pivot sur l’AKI chez l’adulte pour les patients nécessitant une CRRT, une condition qui, selon le communiqué, touche plus de 200 000 adultes par an aux États-Unis.
SeaStar Medical (Nasdaq: ICU) wird die Quartalszahlen Q3 2025 nach Börsenschluss am Donnerstag, dem 13. November 2025 berichten und eine Webcast-Übertragung sowie eine Telefonkonferenz um 16:30 Uhr ET / 14:30 Uhr MT durchführen, mit einer Wiederholung verfügbar nach 19:30 Uhr ET.
SeaStar ist ein kommerziell tätiges Gesundheitsunternehmen, dessen erstes kommerzielles Produkt QUELIMMUNE (SCD-PED) 2024 von der FDA für lebensbedrohliche pädiatrische AKI infolge Sepsis zugelassen wurde. Das firmeneigene Selektive Zytophoretische Gerät (SCD) hat eine Breakthrough Device Designation für sechs Indikationen erhalten, und SeaStar führt eine wesentliche AKI-Studie bei Erwachsenen durch, die eine CRRT benötigen; eine Bedingung, die in der Mitteilung schätzungsweise über 200.000 Erwachsene pro Jahr in den USA betrifft.
SeaStar Medical (ناسداك: ICU) ستُبلغ عن النتائج المالية للربع الثالث 2025 بعد إغلاق السوق يوم الخميس 13 نوفمبر 2025، وستستضيف بثاً مباشراً واتصالاً هاتفياً في الساعة 4:30 مساءً بتوقيت شرق الولايات المتحدة / 2:30 مساءً بتوقيت الجبل مع توافر إعادة بث بعد 7:30 مساءً بتوقيت شرق الولايات المتحدة.
SeaStar هي شركة رعاية صحية في مرحلة التجزئة التجارية، حيث تلقّى أول منتج تجاري لها، QUELIMMUNE (SCD-PED)، اعتماد FDA في 2024 لعجز كلوي حاد عند الأطفال بسبب تعفن الدم (الإنتان). الجهاز الخلوي السيتوفيتازي الانتقائي (SCD) للشركة قد حصل على تصميم جهاز اختراقي لستة مؤشرات وتمضي SeaStar في تجربة حاسمة لـ AKI لدى البالغين الذين يحتاجون إلى CRRT، وهي حالة بحسب الإصدار تؤثر على أكثر من 200,000 بالغ سنويًا في الولايات المتحدة.
- QUELIMMUNE FDA approval in 2024 for pediatric AKI
- SCD awarded Breakthrough Device Designation for six indications
- Pivotal adult AKI trial targeting a 200,000+ patient U.S. population
- Commercial portfolio currently anchored by a single approved product, QUELIMMUNE
- Company must complete a pivotal adult trial to address the larger adult AKI market
DENVER, Nov. 05, 2025 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a commercial-stage healthcare company focused on transforming treatments for critically ill patients facing organ failure and potential loss of life, announced today that it will report its third quarter financial results after market close on Thursday, November 13, 2025, and host a webcast and conference call to discuss its financial results and business progress.
| Date/Time: | Thursday, November 13, 2025, at 4:30 p.m. ET / 2:30 p.m. MT |
| Webcast: | The live webcast and replay can be found here. |
| Dial-in number: | To join the conference call via phone, please pre-register online here to receive a telephone number and unique passcode required to enter the call. |
| A replay of the webcast will be available after 7:30 pm ET and can be accessed here. | |
About SeaStar Medical
SeaStar Medical is a commercial-stage healthcare company focused on transforming treatments for critically ill patients facing organ failure and potential loss of life. The QUELIMMUNE (SCD-PED) therapy is SeaStar Medical’s first commercial product based on its patented Selective Cytopheretic Device (SCD) technology. The QUELIMMUNE (SCD-PED) therapy was approved in 2024 by the U.S. Food and Drug Administration (FDA). It is the only FDA approved product for the ultra-rare condition of life-threatening acute kidney injury (AKI) due to sepsis or a septic condition in critically ill pediatric patients. SeaStar Medical’s Selective Cytopheretic Device (SCD) therapy has been awarded Breakthrough Device Designation for six therapeutic indications by the FDA, enabling the potential for a speedier pathway to approval and preferable reimbursement dynamics at commercial launch. The company is currently conducting a pivotal trial of its SCD therapy in adult patients with AKI requiring continuous renal replacement therapy (CRRT), a life-threatening condition with no effective treatment options that impacts over 200,000 adults in the U.S. annually.
For more information visit www.seastarmedical.com or visit us on LinkedIn or X.
Contact:
SeaStar Investor Relations:
IR@SeaStarMed.com
FAQ
When will SeaStar Medical (ICU) report Q3 2025 results?
What time is the SeaStar Medical (ICU) Q3 2025 webcast and call?
What is QUELIMMUNE and what authorization does it have for SeaStar Medical (ICU)?
How many Breakthrough Device Designations has SeaStar Medical (ICU) received for SCD?
What clinical development is SeaStar Medical (ICU) currently conducting?
Will SeaStar provide a replay of the Q3 2025 webcast for investors?
